Walgreens Boosts Efficiency with Prescription-Filling Robots

Published 2 hours agoWBA

Walgreens Boosts Efficiency with Prescription-Filling Robots

Walgreens is making strides in pharmacy automation by expanding its use of prescription-filling robots. The company has recently opened several automated micro-fulfillment centers across the United States and plans to increase coverage to nearly 6,000 stores within the next year. This initiative aims to enhance efficiency in its pharmacy operations.

The deployment of these technological advancements is proving beneficial, as reports from Livemint indicate that pharmacists' workloads have decreased by at least 25%. This reduction allows pharmacists to dedicate more time to patient care and clinical services. The robots are capable of filling 300 prescriptions per hour, which significantly boosts the speed and precision of the process.

Strategically investing in automation, Walgreens seeks to combat labor shortages and improve its overall operational efficiency. This move not only streamlines pharmacy operations but also underscores Walgreens' commitment to being at the forefront of pharmacy automation, as highlighted by Livemint.

Share this article

Twitter Facebook LinkedIn

Recent Articles

ULA Plans Vulcan Rocket Upgrades to Compete with SpaceX

ULA Plans Vulcan Rocket Upgrades to Compete with SpaceX

6 minutes agoBA

United Launch Alliance (ULA), the joint venture between Boeing and Lockheed Martin, is taking significant steps to upgrade its Vulcan rocket. The goal is to boost its payload capacity to remain competitive in the low Earth orbit satellite launch market, where SpaceX’s Starship currently holds dominance. ULA's strategic enhancement plans are part of a broader effort to meet the growing demands of the LEO market. In a notable development, the Vulcan rocket received certification from the U.S. Space Force in March 2025, allowing it to participate in launching national security satellites. This certification opens doors for ULA to bid for missions under the National Security Space Launch program. Reuters reported on the Vulcan's importance as it completed its second mission successfully on October 4, 2024, from Cape Canaveral. This launch was pivotal in demonstrating the Vulcan's capabilities for potential Pentagon missions. Amid these advancements, Boeing and Lockheed Martin are exploring the possibility of selling ULA to Sierra Space, with negotiations estimated between $2 to $3 billion as of August 2024. This potential acquisition could significantly alter the ownership dynamics of ULA, transitioning from being a joint venture of two defense giant companies to a privately owned entity. Such moves highlight ULA’s commitment to evolving its space launch capabilities in a competitive industry.

CRISPR Therapeutics' Stock Performance and Strategic Progress

CRISPR Therapeutics' Stock Performance and Strategic Progress

21 minutes agoCRSP

CRISPR Therapeutics, listed on NASDAQ as CRSP, is drawing significant attention in the investment community due to its role in advancing gene-editing therapies. The company's stock is currently priced at $35.62 per share, with a market capitalization of approximately $2.92 billion. However, the firm reported an earnings per share of -4.49 as of a recent trading update on May 12, 2025. This suggests investors are closely watching the company's progress and future revenue streams. The launch of Casgevy, a groundbreaking therapy for sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) in collaboration with Vertex Pharmaceuticals, is one of the company's recent milestones. As of early 2025, over 50 treatment centers have been set up worldwide, and cell collection for more than 50 patients has commenced. CRISPR Therapeutics is also pushing forward with several programs across various medical conditions, including B-cell malignancies and cardiovascular diseases, with updates anticipated through the year. Financially, CRISPR Therapeutics is well-positioned with cash reserves amounting to about $1.9 billion, as noted by Investing.com. This financial buffer supports the company's ongoing research and development efforts. As Casgevy's revenue is projected to grow significantly—from $17 million to $135 million by 2025—analysts are keen on the potential clinical breakthroughs from CRISPR's pipeline, especially in autoimmune treatments. Despite challenges such as regulatory hurdles and industry competition, the company's strategic initiatives indicate a proactive approach towards future growth.

U.S.-China Trade Truce Lifts Apple and Tech Shares

U.S.-China Trade Truce Lifts Apple and Tech Shares

1 hours agoAAPL

The recent trade agreement between the U.S. and China has sent ripples across the technology sector, notably boosting tech firms like Apple. The deal involves a temporary reduction of tariffs on each other's goods for a 90-day period, with the U.S. agreeing to lower tariffs to 30% and China to 10%, according to Axios. Global markets have responded positively to the announcement, with Reuters reporting a surge in U.S. stock futures and international indices. This upbeat market sentiment has translated into significant gains for technology companies, especially those with considerable exposure to China. Apple, for example, has witnessed its shares climb to a 52-week high, as noted by 9to5mac. This development reflects a renewed confidence among investors as the trade tensions ease, albeit temporarily. However, the 90-day truce means market watchers are still keeping a close eye on further negotiations for a more lasting resolution between the two economic powerhouses.

AstraZeneca Loses Top Spot as UK's Most Valuable Company

AstraZeneca Loses Top Spot as UK's Most Valuable Company

AstraZeneca has lost its position as the most valuable company in the UK following an announcement by President Trump to significantly lower the prices of prescription drugs in the U.S. The policy aims to reduce drug costs by 30% to 80%, aligning them with prices in other developed countries. This "most favored nation" policy mandates that the U.S. pays no more than the lowest global price for medications. The announcement had a notable impact on the global pharmaceutical market. According to Reuters, AstraZeneca's shares fell by 3.3% amidst a broader market selloff affecting worldwide pharmaceutical stocks. Before this downturn, AstraZeneca's market capitalization had peaked at £200 billion, securing its place as the UK's most valuable company. As of May 12, 2025, AstraZeneca's stock is trading at $67.57, marking a decline of 0.35% from the previous close. This reflects the broader challenges the company is facing in the wake of recent shifts in U.S. drug pricing policy. These market changes underscore the volatility and significant impacts of policy shifts on pharmaceutical valuations.